SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is seeing significant volatility and bullish sentiment driven by a potential short squeeze, ongoing ecosystem developments like MetaMask integration, and speculation around upcoming DAO-approved buyback programs. The community is actively debating the coin's momentum, with many users focused on its potential as a leading Solana DEX and debating whether to accumulate or scalp quick profits.

Maulcoin

Maulcoin is trending as investors debate its long-term viability, with the community actively split between supporters pushing for growth around upcoming May 4th milestones and critics labeling the project a potential rug pull. Sentiment remains highly polarized, driven by ongoing internal tensions and aggressive cross-platform promotion efforts.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is currently a focal point for investors due to positive clinical data for its lead oncology programs, alongside ongoing institutional accumulation and anticipation of near-term catalyst readouts. The community is actively debating the company's valuation, pipeline depth in synthetic lethality, and the potential for a strategic M&A event given its highly proprietary platform.

KAT is a defi token with governance-like mechanics for Katana.  It is designed to function as a lever for directing capital: users that lock KAT receive a voting version of KAT — vKAT — in return. vKAT underpins key aspects of the chain’s economy, providing rewards to those users that participate. these fee-based rewards function as an incentive for KAT holders to engage in cooperative, positive-sum behavior.

Katana

Katana is gaining significant market attention as traders react to new tokenomics integrations and speculation regarding potential migration plans, fueling intense community debate between bullish growth projections and concerns over volatility. The asset remains a focal point for active trading communities discussing high volume, recent price consolidation, and the impact of its ecosystem's expansion on long-term utility.

Dave, Inc. is a digital banking service. Its products include a budgeting tool to help members manage their upcoming bills to avoid overspending, cash advances through its flagship ExtraCash product to help members avoid punitive overdraft fees, a Side Hustle product, where Dave helps connect members with supplemental work opportunities, and Dave Banking, a modern checking account experience with valuable tools for building long-term financial health. The company was founded by Jason Wilk, Paras Chitrakar, and John Wolanin in October 2015 and is headquartered in Los Angeles, CA.

Dave Inc - Ordinary Shares - Class A

Dave Inc. is trending as traders closely monitor its technical breakout potential and strong Q3 performance, with the community highlighting its high operating leverage and the disruptive potential of its AI-powered underwriting platform. Investors remain focused on the company's path to profitability and its strategic positioning in the neobanking sector, often drawing comparisons to other high-growth fintech peers.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is currently facing significant volatility following a convertible notes offering and insider share sales, leaving the community divided between long-term confidence in its gene-editing pipeline and frustration over the company's management and share performance. Traders are closely monitoring upcoming clinical data readouts and potential acquisition interest while debating whether the current price represents a generational buying opportunity or ongoing stagnation.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and social media users react to a high-profile security incident involving an evacuation at the White House Correspondents' Dinner, fueling intense community debate regarding the event's authenticity and political motives. Conversations are heavily polarized, with users analyzing potential market impacts on the stock while debating the broader context of the administration's political challenges and the ongoing scrutiny surrounding the company's leadership.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is experiencing extreme intraday volatility as retail investors debate whether recent earnings and OEM-related updates represent a legitimate long-term pivot or an orchestrated pump-and-dump scheme. The community remains deeply polarized, with bulls pointing to the company's expanding commercial pipeline in the EV and data center sectors, while bears highlight the ongoing lack of mass-production revenue and the stock's tendency to see significant gains erased by aggressive short-selling.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors focus on the potential appointment of a former company executive to lead the FDA's CBER, a move viewed as highly favorable for the pending approval of its Duchenne muscular dystrophy treatment, deramiocel. The community remains hyper-focused on labeling negotiations and the broader market implications of this prospective leadership shift on the drug's commercial path.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The biotech sector is experiencing high investor interest driven by a wave of strategic M&A activity and positive clinical guideline updates, such as NCCN's expanded recommendations for oncology therapies. Investors are actively discussing the potential for structural squeezes in heavily shorted tickers and monitoring the interplay between biotech's clinical momentum and broader market macro volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunic (NASDAQ:IMUX) Shares to Reverse Split on Monday, April 27th

Immunic, Inc. (NASDAQ:IMUX - Free Report) shares are set to reverse split on Monday, April 27th. The 1-10 reverse split was announced on Thursday, April 23rd. The number of shares owned by...

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Immunic, Inc. Announces 1-for-10 Reverse Stock Split Immunic, Inc. Announces 1-for-10 Reverse Stock Split PR Newswire NEW YORK, April 23, 2026 NEW YORK, April 23, 2026 /PRNewswire/ -- Immunic, Inc...

Immunic (NASDAQ:IMUX) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Immunic from a "hold" rating to a "sell" rating in a research note on Sunday...

Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says

Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety.read more...

Immunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of "Moderate Buy" from Analysts

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine research firms that are presently covering the firm, MarketBeat reports. One analyst has...

Immunic Stock Scheduled to Reverse Split on Monday, April 27th (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX - Free Report) shares are set to reverse split before the market opens on Monday, April 27th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, April 26th...

Immunic (NASDAQ:IMUX) Downgraded to Hold Rating by D. Boral Capital

D. Boral Capital cut Immunic from a "buy" rating to a "hold" rating in a research note on Wednesday...

Wall Street Zen Upgrades Immunic (NASDAQ:IMUX) to Hold

Wall Street Zen raised shares of Immunic from a "sell" rating to a "hold" rating in a research note on Saturday...

Immunic to Participate in Scientific and Medical Conferences in April

Immunic to Participate in Scientific and Medical Conferences in April Immunic to Participate in Scientific and Medical Conferences in April PR Newswire NEW YORK, April 9, 2026 NEW YORK, April 9, 2026...

<ul class="summary-bullets"><li>IMUX shares have consistently traded above $1 since February 27.</li><li>The company appointed Jon Congleton, CEO of Mineralys Therapeutics, to its board of directors on Tuesday.</li><li>It recently closed a private placement of up to $400 million to support late-stage trials for the treatment of multiple sclerosis.</li></ul>Shares of Immunic, Inc (IMUX) gained around 7% on Wednesday after the company said it had regained compliance with Nasdaq’s listing rules on March 26.The firm regained compliance after the stock closed at or above $1 for at least 20 consecutive business days. The update removes concerns about a potential delisting from the Nasdaq Capital Market.<a href="https://stocktwits.com/symbol/IMUX">IMUX shares</a> have consistently&nbsp;traded above $1 since February 27.On Tuesday, the company appointed Jon Congleton, CEO of Mineralys Therapeutics, to its board of directors.&nbsp;<h2 class="st-heading-2">Immunic Secures Patent And Raises $400 Million</h2>Last month, the European Patent Office granted Immunic a key patent covering dosing regimens for its lead drug, Vidofludimus Calcium, to treat patients with&nbsp;multiple sclerosis. The protection is expected to last until 2038, with a potential extension to 2043.&nbsp;The patent broadly covers multiple forms of the drug, ensuring strong exclusivity across Europe and building on earlier approval from the United States Patent and Trademark Office.The company also closed a private placement of up to $400 million, led by BVF Partners. Immunic secured $200 million upfront, with additional funding tied to future warrants. The company said the funds will support late-stage trials for multiple sclerosis, aimed at helping slow disease progression.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits remained in the ‘bearish’ zone over the past 24 hours.One user highlighted the potential for a reverse share split.<stembedurl>https://stocktwits.com/ccledez/message/649165039</stembedurl>Another user was bullish about Congleton’s appointment.<stembedurl>https://stocktwits.com/Mvvh1987/message/649022575</stembedurl>Year-to-date, the stock has gained more than 113%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

IMUX Stock Jumps 6% Pre-Market Today – Here’s The Latest Update On Its Compliance With Nasdaq Listing Rules 

Shares of Immunic, Inc (IMUX) gained around 6% in pre-market trading on Wednesday after the company said it had regained compliance with Nasdaq’s listing rules on March 26.

Equity

The company regained compliance after the stock closed at or above $1 for at least 20 consecutive business days.

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on multiple sclerosis, celiac disease and other neurologic and gastrointestinal disorders. The firm's products include IMU-838, IMU-856, and IMU-381. The company was founded in 2016 and is headquartered in New York, NY.

Current Price	$0.8801
Prev Close	$0.9183
Open	$0.90
Dividend Yield	0.00%
50-Day Moving Average	$1.09
Beta	1.45
Avg. Volume	3.1M
PE Ratio	-1.18

52-Week High	$1.51
52-Week Low	$0.5062
Market Capitalization	$119.88M
EPS (Annual)	-$0.6242
Price to Book	-15.88
Revenue Per Employee	$0.00

IMUX
Immunic Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IMUX News

IMUXImmunic Inc